• About Good Acts
  • Veterans Resources
  • From Pharms to Farms | A Veteran’s Road to Freedom
  • Petition to Educate the DEA on the Medical Benefits of Cannabis
Good Acts

The best road to progress is freedom's road. - JFK

Florida

Dexanabinol

Dexanabinol
HU-211 structure.png
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • (6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
CAS Number
  • 112924-45-5 ☑Y
PubChem CID
  • 107778
ChemSpider
  • 96934 ☒N
UNII
  • R6VT8U5372
CompTox Dashboard (EPA)
  • DTXSID40150235 Edit this at Wikidata
ECHA InfoCard100.201.022 Edit this at Wikidata
Chemical and physical data
FormulaC25H38O3
Molar mass386.567 g/mol g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • Oc2cc(cc1OC([C@H]3C/C=C(\C[C@@H]3c12)CO)(C)C)C(C)(C)CCCCCC
InChI
  • InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1 ☒N
  • Key:SSQJFGMEZBFMNV-PMACEKPBSA-N ☒N
 ☒N☑Y (what is this?)  (verify)

Dexanabinol (HU-211 or ETS2101[1]) is a synthetic cannabinoid derivative in development by e-Therapeutics plc. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210.[2] Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead has NMDA antagonist effects.[3] It therefore does not produce cannabis-like effects, but is anticonvulsant and neuroprotective, and is widely used in scientific research as well as currently being studied for applications such as treating head injury, stroke, or cancer.[4][5][6] It was shown to be safe in clinical trials[7] and is currently undergoing Phase I trials for the treatment of brain cancer[8] and advanced solid tumors.[9]

Contents

  • 1 Clinical Trials
  • 2 Legal status
    • 2.1 United States
      • 2.1.1 Alabama
      • 2.1.2 Florida
      • 2.1.3 Vermont
  • 3 References

Clinical Trials

Dexanabinol has been studied in IV administration and oral dosing.[10] e-Therapeutics is evaluating the compound in clinical trials for brain and solid cancers.[11] Phase II studies are planned based on the results of the current trials.

A phase 1b study for hepatocellular carcinoma and pancreatic cancer was started in 2015.[12]

Legal status

HU-211 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971,[13] so the signatory countries to these international drug control treaties are not required by said treaties to control HU-211.

United States

HU-211 is not listed in the list of scheduled controlled substances in the USA.[14] It is therefore not scheduled at the federal level in the United States, but it is possible that HU-211 could legally be considered an analog of Delta-8-THC (one of the THC isomers which is in Schedule I under the designation of "Tetrahydrocannabinols"), and therefore sales or possession could potentially be prosecuted under the Federal Analogue Act.[15]

Alabama

HU-211 is a Schedule I controlled substance in Alabama.[16]

10.

(6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol, some trade or other names: HU-211, Dexanabinol.

Florida

HU-211 is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[17] It is listed twice under the hallucinogic substances subcategory:

“ (c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of their salts, isomers, including optical, positional, or geometric isomers, homologues, nitrogen-heterocyclic analogs, esters, ethers, and salts of isomers, homologues, nitrogen-heterocyclic analogs, esters, or ethers, if the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation or class description:

...

130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

...

190. Synthetic Cannabinoids.—Unless specifically excepted or unless listed in another schedule or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation that contains any quantity of a synthetic cannabinoid found to be in any of the following chemical class descriptions, or homologues, nitrogen-heterocyclic analogs, isomers (including optical, positional, or geometric), esters, ethers, salts, and salts of homologues, nitrogen-heterocyclic analogs, isomers, esters, or ethers, whenever the existence of such homologues, nitrogen-heterocyclic analogs, isomers, esters, ethers, salts, and salts of isomers, esters, or ethers is possible within the specific chemical class or designation. Since nomenclature of these synthetically produced cannabinoids is not internationally standardized and may continually evolve, these structures or the compounds of these structures shall be included under this subparagraph, regardless of their specific numerical designation of atomic positions covered, if it can be determined through a recognized method of scientific testing or analysis that the substance contains properties that fit within one or more of the following categories:
a. Tetrahydrocannabinols.—Any tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, the synthetic equivalents of the substances contained in the plant or in the resinous extracts of the genus Cannabis, or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity, including, but not limited to, Delta 9 tetrahydrocannabinols and their optical isomers, Delta 8 tetrahydrocannabinols and their optical isomers, Delta 6a,10a tetrahydrocannabinols and their optical isomers, or any compound containing a tetrahydrobenzo[c]chromene structure with substitution at either or both the 3-position or 9-position, with or without substitution at the 1-position with hydroxyl or alkoxy groups, including, but not limited to:

...

(III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
”

Vermont

Effective January 1, 2016, HU-211 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."[18]

“Hallucinogenic Drug” means those specified in Section 7 of this rule including stramonium, mescaline or peyote, lysergic acid diethylamide, and psilocybin, and all synthetic equivalents of chemicals contained in resinous extractives of Cannabis sativa, or any salts or derivatives or compounds of any preparations or mixtures thereof, and any other substance having a hallucinogenic effect in the regulations adopted by the Board of Health under 18 V.S.A.§ 4202.

...

• HU-211, Dexanabinol; (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2- yl)- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR (6aS, 10aS)-9-(hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol

References

  1. ^ "e-therapeutics Clinical Development Pipeline". Archived from the original on 2013-01-26. Retrieved 2012-10-23.
  2. ^ Pop E (September 2000). "Nonpsychotropic synthetic cannabinoids". Current Pharmaceutical Design. 6 (13): 1347–60. doi:10.2174/1381612003399446. PMID 10903397.
  3. ^ Feigenbaum JJ; et al. (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America. 86 (23): 9584–7. doi:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719.
  4. ^ Biegon A; Joseph AB (August 1995). "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research. 17 (4): 275–80. PMID 7477742.
  5. ^ Darlington CL (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs : the Investigational Drugs Journal. 6 (10): 976–9. PMID 14534855.
  6. ^ Vink R; Nimmo AJ (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics. 6 (1): 28–42. doi:10.1016/j.nurt.2008.10.036. PMC 5084254. PMID 19110197.
  7. ^ Maas AI; et al. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". Lancet Neurol. 5 (1): 38–45. doi:10.1016/S1474-4422(05)70253-2. PMID 16361021.
  8. ^ University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.
  9. ^ "A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours". ClinicalTrials.gov. NIH. January 26, 2015.
  10. ^ "e-Therapeutics Reports Progress in ETS2101 Phase 1a and Oral Dosing Studies" (PDF). 18 December 2014. Archived from the original (PDF) on 5 February 2015.
  11. ^ "Clinical Development Pipeline". Archived from the original on February 5, 2015. Retrieved Feb 5, 2015.
  12. ^ "A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-09-18.
  13. ^ UN International Drug Control Conventions
  14. ^ §1308.11 Schedule I.
  15. ^ Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary
  16. ^ "Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd". March 2014. Retrieved 2 February 2017.
  17. ^ Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
  18. ^ Vermont DOH - Regulated Drug Rule 2016 .PDF
Cannabinoids
Phytocannabinoids
  • Alkylamides
  • Caryophyllene
  • CBC
  • CBD
  • CBDV
  • CBG
  • CBL
  • CBDL
  • CBN
  • CBV
  • Epigallocatechin gallate
  • Gallocatechol
  • Perrottetinene
  • Serinolamide A
  • THC
  • THC-C4
  • THCA
  • THCV
  • Yangonin
  • Active metabolites:
  • 11-COOH-THC
  • 11-OH-THC
Endocannabinoids
  • Arachidonoyl ethanolamide (AEA; anandamide)
  • 2-Arachidonoylglycerol (2-AG)
  • 2-Arachidonyl glyceryl ether (2-AGE; noladin ether)
  • 2-Oleoylglycerol (2-OG)
  • N-Arachidonoyl dopamine (NADA)
  • N-Arachidonylglycine (NAGly)
  • N-Arachidonoyl serotonin (AA-5-HT)
  • Docosatetraenoylethanolamide (DEA)
  • Lysophosphatidylinositol (LPI)
  • Oleamide
  • Oleoylethanolamide (OEA)
  • Palmitoylethanolamide (PEA)
  • RVD-Hpα
  • Stearoylethanolamide (SEA)
  • O-Arachidonoyl ethanolamine (O-AEA; virodhamine)
Synthetic
cannabinoids
Classical cannabinoids
(dibenzopyrans)
  • A-40174
  • A-41988
  • Ajulemic acid
  • AM-087
  • AM-411
  • AM-855
  • AM-905
  • AM-906
  • AM-919
  • AM-938
  • AM-2389
  • AM-4030
  • AMG-1
  • AMG-3
  • AMG-36
  • AMG-41
  • Dexanabinol (HU-211)
  • DMHP
  • Dronabinol
  • HHC
  • HU-210
  • HU-243
  • JWH-051
  • JWH-133
  • JWH-161
  • JWH-359
  • KM-233
  • L-759,633
  • L-759,656
  • Levonantradol (CP 50,5561)
  • Menabitan
  • Nabazenil
  • Nabidrox (Canbisol)
  • Nabilone
  • Nabitan
  • Naboctate
  • O-774
  • O-806
  • O-823
  • O-1057
  • O-1125
  • O-1238
  • O-2113
  • O-2372
  • O-2545
  • O-2694
  • Parahexyl
  • Pirnabine
  • THC-O-acetate
  • THC-O-phosphate
Non-classical
cannabinoids
  • Cannabicyclohexanol
  • CBD-DMH
  • CP 47,497
  • (C6)-CP 47,497
  • (C9)-CP 47,497
  • CP 55,244
  • CP 55,940
  • HU-308
  • HU-320
  • HU-331
  • HU-336
  • HU-345
  • HUF-101
  • Nonabine
  • O-1871
  • Tinabinol
Benzoylindoles
  • AM-630
  • AM-679
  • AM-694
  • AM-1241
  • AM-2233
  • GW-405,833 (L-768,242)
  • Pravadoline
  • RCS-4
  • WIN 54,461
Naphthoylindoles
  • AM-1220
  • AM-1221
  • AM-1235
  • AM-2201
  • AM-2232
  • EAM-2201
  • FUB-JWH-018
  • JWH-007
  • JWH-015
  • JWH-018
  • JWH-019
  • JWH-073
  • JWH-081
  • JWH-098
  • JWH-116
  • JWH-122
  • JWH-149
  • JWH-164
  • JWH-182
  • JWH-193
  • JWH-198
  • JWH-200
  • JWH-210
  • JWH-398
  • JWH-424
  • MAM-2201
  • NE-CHMIMO
Naphthoylindazoles
  • THJ-018
  • THJ-2201
Pyrrolobenzoxazines
  • WIN 55,212-2
Naphthylmethylindoles
  • JWH-175
  • JWH-176
  • JWH-184
  • JWH-185
  • JWH-196
Phenylacetylindoles
  • Cannabipiperidiethanone
  • JWH-167
  • JWH-203
  • JWH-249
  • JWH-250
  • JWH-251
  • JWH-302
  • RCS-8
Indole-3-carboxamides
  • 5F-ADBICA
  • 5F-MDMB-PICA
  • 5F-NNE1
  • 5F-PCN
  • 5F-SDB-006
  • AB-FUBICA
  • AB-PICA
  • ADBICA
  • ADB-FUBICA
  • APICA
  • CUMYL-PICA
  • FDU-NNE1
  • MDMB-CHMICA
  • MMB-CHMICA
  • MMB-2201
  • MN-25 (UR-12)
  • NNE1
  • PX-1
  • Org 28312
  • Org 28611
  • SDB-006
  • STS-135
Indole-3-carboxylates
  • 5F-PB-22
  • FDU-PB-22
  • FUB-PB-22
  • QUCHIC (BB-22)
  • QUPIC (PB-22)
  • NM-2201
Tetramethylcyclo-
propanoylindoles
  • A-796,260
  • A-834,735
  • FUB-144
  • UR-144
  • XLR-11
  • XLR-12
Indazole-3-
carboxamides
  • 5F-ADB
  • 5F-ADB-PINACA
  • 5F-AMB
  • 5F-APINACA
  • 5F-CUMYL-PINACA
  • 5F-EDMB-PINACA
  • 5F-EMB-PINACA
  • AB-CHMINACA
  • AB-FUBINACA
  • AB-PINACA
  • ADB-CHMINACA
  • ADB-FUBINACA
  • ADB-PINACA
  • Adamantyl-THPINACA
  • ADSB-FUB-187
  • AMB-CHMINACA
  • AMB-FUBINACA
  • APINACA (AKB48)
  • APP-FUBINACA
  • CUMYL-4CN-BINACA
  • CUMYL-PINACA
  • CUMYL-THPINACA
  • FUB-APINACA
  • MDMB-FUBINACA
  • MDMB-CHMINACA
  • MN-18
  • PX-2
  • PX-3
Tetramethylcyclo-
propanoylindazoles
  • FAB-144
Naphthoylpyrroles
  • JWH-030
  • JWH-147
  • JWH-307
Eicosanoids
  • ACEA
  • ACPA
  • Methanandamide (AM-356)
  • O-1812
Pyrazolecarboxamides
  • 5F-AB-FUPPYCA
  • AB-CHFUPYCA
Others
  • 2F-QMPSB
  • 4-HTMPIPO
  • A-836,339
  • Abnormal cannabidiol
  • AB-001
  • BzODZ-EPyr
  • AM-1248
  • AM-1714
  • AZ-11713908
  • AZD-1940
  • BAY 38-7271
  • BAY 59-3074
  • BIM-018
  • CB-13
  • CBS-0550
  • 5F-CUMYL-P7AICA
  • CUMYL-PEGACLONE
  • FUBIMINA
  • GW-842,166X
  • JTE 7-31
  • LASSBio-881
  • LBP-1
  • Leelamine
  • MDA-19
  • MEPIRAPIM
  • NESS-040C5
  • NMP-7
  • O-1269
  • O-1602
  • Olorinab
  • PF-03550096
  • PSB-SB-1202
  • PTI-1
  • PTI-2
  • QMPSB
  • S-444,823
  • SER-601
  • Tedalinab
  • WIN 56,098
Allosteric CBR ligands
  • Org 27569
  • RTI-371
  • Pregnenolone
Endocannabinoid
enhancers

(inactivation inhibitors)
  • 4-Nonylphenylboronic acid
  • AM-404
  • Arachidonoyl serotonin
  • BIA 10-2474
  • Biochanin A
  • Genistein
  • Guineesine
  • IDFP
  • JNJ-42165279
  • JZL184
  • JZL195
  • Kaempferol
  • LY-2183240
  • MK-4409
  • Oleoylethanolamide (OEA)
  • Palmitoylethanolamide (PEA)
  • PF-04457845
  • PF-3845
  • URB-597
  • URB-602
  • URB-754
  • VDM-11
Anticannabinoids
(antagonists/inverse
agonists/antibodies)
  • AM-251
  • AM-630
  • AM-6545
  • BML-190
  • Drinabant (AVE1625)
  • Hemopressin
  • Ibipinabant (SLV319)
  • JTE-907
  • LY-320,135
  • MK-9470
  • NESS-0327
  • O-1918
  • O-2050
  • Otenabant (CP-945,598)
  • PF-514273
  • PipISB
  • PSB-SB-487
  • Rimonabant (SR141716)
  • Rosonabant (E-6776)
  • SR-144,528
  • Surinabant (SR147778)
  • Taranabant (MK-0364)
  • TM-38837
  • VCHSR
  • See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
  • List of: AM cannabinoids
  • JWH cannabinoids
  • Designer drugs § Synthetic cannabimimetics
Ionotropic glutamate receptor modulators
AMPAR
  • Agonists: Main site agonists: 5-Fluorowillardiine
  • AMPA
  • Domoic acid
  • Glutamate
  • Ibotenic acid
  • Proline
  • Quisqualic acid
  • ; Positive allosteric modulators: Aniracetam
  • BIIB-104 (PF-04958242)
  • Cyclothiazide
  • CX-516
  • CX-546
  • CX-614
  • Farampator (CX-691, ORG-24448)
  • CX-717
  • CX-1739
  • Diazoxide
  • Hydrochlorothiazide (HCTZ)
  • IDRA-21
  • LY-404187
  • LY-503430
  • Mibampator (LY-451395)
  • Nooglutyl
  • ORG-26576
  • Oxiracetam
  • PEPA
  • Piracetam
  • Pramiracetam
  • S-18986
  • Tulrampator (S-47445, CX-1632)
  • Antagonists:
  • Becampanel
  • Caroverine
  • CNQX
  • Dasolampanel
  • DNQX
  • Fanapanel (MPQX)
  • Kaitocephalin
  • Kynurenic acid
  • Kynurenine
  • Licostinel (ACEA-1021)
  • NBQX
  • Selurampanel
  • Tezampanel
  • Theanine
  • Topiramate
  • Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
  • Cyclopropane
  • Enflurane
  • Ethanol (alcohol)
  • Evans blue
  • GYKI-52466
  • Halothane
  • Irampanel
  • Isoflurane
  • Perampanel
  • Pregnenolone sulfate
  • Sevoflurane
  • Talampanel; Unknown/unsorted antagonists: Minocycline
KAR
  • Agonists: Main site agonists:
  • 5-Iodowillardiine
  • AMPA
  • Domoic acid
  • Glutamate
  • Ibotenic acid
  • Kainic acid
  • Proline
  • Quisqualic acid
  • ; Positive allosteric modulators: Cyclothiazide
  • Diazoxide
  • Enflurane
  • Halothane
  • Isoflurane
  • Antagonists:
  • CNQX
  • Dasolampanel
  • DNQX
  • Kaitocephalin
  • Kynurenic acid
  • Licostinel (ACEA-1021)
  • NBQX
  • NS102
  • Selurampanel
  • Tezampanel
  • Theanine
  • Topiramate
  • UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
  • Enflurane
  • Ethanol (alcohol)
  • Evans blue
  • Pregnenolone sulfate
NMDAR
  • Agonists: Main site agonists:
  • Aspartate
  • Glutamate
  • Homocysteic acid (L-HCA)
  • Homoquinolinic acid
  • Ibotenic acid
  • NMDA
  • Proline
  • Quinolinic acid
  • Tetrazolylglycine
  • Theanine; Glycine site agonists:
  • ACC (ACPC)
  • ACPD
  • Apimostinel (NRX-1074)
  • D-Alanine
  • D-Cycloserine
  • D-Serine
  • Dimethylglycine
  • Glycine
  • HA-966
  • L-Alanine
  • L-Serine
  • Milacemide
  • Neboglamine (nebostinel)
  • Rapastinel (GLYX-13)
  • Sarcosine; Polyamine site agonists: Neomycin
  • Spermidine
  • Spermine; Other positive allosteric modulators:
  • DHEA (prasterone)
  • DHEA sulfate (prasterone sulfate)
  • Pregnenolone sulfate
  • Antagonists: Competitive antagonists: AP5 (APV)
  • AP7
  • CGP-37849
  • Kaitocephalin
  • LY-235959
  • Midafotel (d-CPPene)
  • PEAQX
  • Perzinfotel
  • Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
  • 5,7-DCKA
  • 7-CKA
  • ACC
  • Apimostinel (NRX-1074)
  • AV-101
  • Carisoprodol
  • CNQX
  • D-Cycloserine
  • DNQX
  • Felbamate
  • Gavestinel
  • Kynurenic acid
  • Kynurenine
  • Licostinel (ACEA-1021)
  • Meprobamate
  • Rapastinel (GLYX-13)
  • ; Polyamine site antagonists:
  • Diaminopropane
  • Diethylenetriamine
  • Huperzine A
  • Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
  • 3-HO-PCP
  • 3-MeO-PCE
  • 3-MeO-PCMo
  • 3-MeO-PCP
  • 4-MeO-PCP
  • 8A-PDHQ
  • 18-MC
  • α-Endopsychosin
  • Alaproclate
  • Alazocine (SKF-10047)
  • Amantadine
  • Aptiganel
  • Arketamine
  • Budipine
  • Coronaridine
  • Delucemine (NPS-1506)
  • Dexoxadrol
  • Dextrallorphan
  • Dextromethadone
  • Dextromethorphan
  • Dextrorphan
  • Dieticyclidine
  • Diphenidine
  • Dizocilpine
  • Ephenidine
  • Esketamine
  • Etoxadrol
  • Eticyclidine
  • Fluorolintane
  • Gacyclidine
  • Ibogaine
  • Ibogamine
  • Indantadol
  • Ketamine
  • Ketobemidone
  • Lanicemine
  • Levomethadone
  • Levomethorphan
  • Levomilnacipran
  • Levorphanol
  • Loperamide
  • Memantine
  • Methadone
  • Methorphan
  • Methoxetamine
  • Methoxphenidine
  • Milnacipran
  • Morphanol
  • NEFA
  • Neramexane
  • Nitromemantine
  • Noribogaine
  • Norketamine
  • Orphenadrine
  • PCPr
  • PD-137889
  • Pethidine (meperidine)
  • Phencyclamine
  • Phencyclidine
  • Propoxyphene
  • Remacemide
  • Rhynchophylline
  • Rimantadine
  • Rolicyclidine
  • Sabeluzole
  • Tabernanthine
  • Tenocyclidine
  • Tiletamine
  • Tramadol; Ifenprodil (NR2B) site antagonists:
  • Besonprodil
  • Buphenine (nylidrin)
  • Eliprodil
  • Haloperidol
  • Isoxsuprine
  • Rislenemdaz (CERC-301, MK-0657)
  • Traxoprodil (CP-101606); NR2A-selective antagonists:
  • ; Cations: Hydrogen
  • Magnesium
  • Zinc; Alcohols/volatile anesthetics/related: Benzene
  • Butane
  • Chloroform
  • Cyclopropane
  • Desflurane
  • Diethyl ether
  • Enflurane
  • Ethanol (alcohol)
  • Halothane
  • Hexanol
  • Isoflurane
  • Methoxyflurane
  • Nitrous oxide
  • Octanol
  • Sevoflurane
  • Toluene
  • Trichloroethane
  • Trichloroethanol
  • Trichloroethylene
  • Urethane
  • Xenon
  • Xylene; Unknown/unsorted antagonists:
  • Bumetanide
  • Caroverine
  • Conantokin
  • D-αAA
  • Dexanabinol
  • Flufenamic acid
  • Flupirtine
  • Furosemide
  • Hodgkinsine
  • Metaphit
  • Minocycline
  • MPEP
  • Niflumic acid
  • Pentamidine
  • Pentamidine isethionate
  • Piretanide
  • Psychotridine
  • Transcrocetin (saffron)
  • Unsorted: Allosteric modulators: AGN-241751
  • See also: Receptor/signaling modulators
  • Metabotropic glutamate receptor modulators
  • Glutamate metabolism/transport modulators
source: http://en.wikipedia.org/wiki/Dexanabinol
  • This page was last edited on 27 November 2019, at 02:14 (UTC).
  • Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
  • Privacy policy
  • About Wikipedia
  • Disclaimers
  • Contact Wikipedia
  • Developers
  • Statistics
  • Cookie statement
  • Mobile view
  • Wikimedia Foundation
  • Powered by MediaWiki

Please consider signing this Petition to Educate the DEA and UN on the medical benefits of Cannabis.

State Resources

  • Florida

    Florida

    January 22, 2018
  • Repetitive Transcranial Magnetic Stimulation | rTMS | Depression Therapy for Veterans at the Waco, Tx. VA

    Repetitive Transcranial Magnetic Stimulation | rTMS | Depression Therapy for Veterans at the Waco, Tx. VA

    February 22, 2019
  • San Diego Vet Centers

    San Diego Vet Centers

    January 22, 2018

Resources

  • VA Administration Sets National Policy Allowing Robotic Prosthetics

    VA Administration Sets National Policy Allowing Robotic Prosthetics

    December 26, 2015
  • VA benefits for Veterans of the Armed Forces of the United States of America

    VA benefits for Veterans of the Armed Forces of the United States of America

    March 18, 2016
  • Human Tissue Regeneration with Pigs Bladder Powder

    Human Tissue Regeneration with Pigs Bladder Powder

    March 18, 2016

Latest Posts

  • The American Legion Urge the Drug Enforcement Agency to License Privately-Funded Medical Marijuana Production Operations in the United States

    The American Legion Urge the Drug Enforcement Agency to License Privately-Funded Medical Marijuana Production Operations in the United States

    September 11, 2016
  • Compassionate Care Act of 2015 in Texas Discriminates Against Veterans

    Compassionate Care Act of 2015 in Texas Discriminates Against Veterans

    March 27, 2016
  • National Second Opinion Day 4/20/16 - All Veterans Ask VA for Second Opinion

    National Second Opinion Day 4/20/16 – All Veterans Ask VA for Second Opinion

    March 18, 2019

FOIA Contacts

  • Veterans Affairs | Veteran Claims File Request

  • Postal Inspection Service

  • USPS Field Office

Copyright © 2019 Good Acts.

Omega WordPress Theme by ThemeHall